Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview

Author(s): L. Fernandez, R.H. Bustos*, C. Zapata, J. Garcia, E. Jauregui, G.M. Ashraf.

Journal Name: Current Protein & Peptide Science

Volume 19 , Issue 10 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Currently it is well known that all biological drugs, including those with a fully human structure, are capable of inducing a host immune response known as immunogenicity [1]. The presence of ADAs can condition the drug´s level and action, thus modifying the therapeutic effect and even the safety profile by its mechanism of action - neutralizing or non-neutralizing - and / or an increase in its clearance. Immunogenicity is a dynamic factor to be taken into account in biological therapy, especially in long-term treatments, and as a relevant aspect in the assessment of secondary response loss [2]. With the above, not only the knowledge but also the management of the immunogenicity of the different biological treatments, represent a useful instrument for optimization of the strategies of use for each drug, and in the design of predictive models of response, which finally permits a significant improvement in the efficacy and safety profile, aiming to a personalization of the therapies, especially in patients with autoimmune diseases, genetic disorders and cancer [3]. This review summarizes the events of immunogenicity that produce the biological drug, the factor that influence to immunogenicity and the assessment of immunogenicity.

Keywords: Immunogenicity, biosensor, peptide, biological drugs, anti-drugs antibodies, ADAs.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 10
Year: 2018
Page: [958 - 971]
Pages: 14
DOI: 10.2174/1389203718666170828123449
Price: $58

Article Metrics

PDF: 56
HTML: 4
EPUB: 1
PRC: 2